Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

New oncogene target for breast cancer: LMTK3

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.06.11
Views: 8028

Prof Justin Stebbing - Imperial College London, UK

Prof Justin Stebbing discusses his research which identified a new protein involved in the development of drug resistance in breast cancer. It is hoped that this can ultimately be used as a target for new treatments. In the study, researchers from Imperial College London found that blocking a protein called LMTK3 in human cancer cells that were resistant to tamoxifen made the cells more responsive.


Prof Stebbing explains how this protein was identified and talks about the other research he was presenting at the ASCO meeting. This research included the results of a study investigating the links between weight gain and poor response to chemotherapy, a paper on circulating tumour cells in prostate cancer and a presentation looking at polymorphism in the IGFR1 gene as a predictive factor for patient outcome.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation